Cancer biotech ASLAN Pharmaceuticals sets terms for $60 million IPO

Shutterstock photo

ASLAN Pharmaceuticals, a Singapore biotech developing cancer therapies using the HER pathway, announced terms for its IPO on Monday.

The Singapore-based company plans to raise $60 million by offering 37.5 million shares at a price of $1.61. At the midpoint of the proposed range, ASLAN Pharmaceuticals would command a fully diluted market value of $283 million.

ASLAN Pharmaceuticals was founded in 2010 and plans to list on the Nasdaq under the symbol ASLN. Leerink Partners and Piper Jaffray are the joint bookrunners on the deal.

The article Cancer biotech ASLAN Pharmaceuticals sets terms for $60 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?